RenovoRx RNXT 深 沪
等待开盘 08-08 09:30:00 美东时间
1.20
0.000
0.00%
华盛通- 最 高1.24
- 今 开1.23
- 成交量 4.08万股
- 最 低 1.17
- 昨 收 1.20
- 总市值 4388.66万
- 52周最高 1.6899
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.75
- 委 比 34.06%
- 总股本 3657.22万
- 历史最高 16.74
- 量 比 0.50
- 振 幅 5.83%
- 历史最低 0.5306
- 每 手 1
- 风险率 0.27%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多RenovoRx Expands RenovoCath Commercial Reach To 13 Cancer Centers
RenovoRx increases its commercial footprint to thirteen leading National Cancer Institute-designated and community centers approved to purchase RenovoCathFour active cancer center customers are currently purchasing and
08-06 20:38
RenovoRx Expands U.S. Commercialization Efforts for the RenovoCath® Device with Growing Customer Demand and Key Leadership Hire
<p>RenovoRx expands its commercial presence with 13 cancer centers approved to purchase RenovoCath, including 4 repeat customers. The company hires Philip Stocton as Senior Director of Sales, leveraging his 25+ years in MedTech and interventional oncology. This growth underscores the demand for localized tumor treatments beyond traditional IV chemotherapy. RenovoCath's adoption highlights its potential to improve patient outcomes by reducing syst...
08-06 12:30
RenovoRx Launches PanTheR Post-Marketing Registry Study, To Expand Safety And Performance Data Of FDA-Cleared RenovoCath Device, And Associated Survival Outcomes In Patients Diagnosed With Solid Tumors
Several Esteemed Cancer Centers to Commence Patient Enrollment Before the End of SeptemberThe Registry Study, Known as PanTheR, will Expand the Safety and Performance Data of the FDA-Cleared RenovoCath® Device, and
07-28 20:36
美股大行评级 | 潜在涨幅6326.33%！Ascendiant Capital上调Plus Therapeutics目标价至20.5美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1137665801621229569.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Ascendiant Capital：维持Plus Therapeutics(PSTV)"买入"评级，目标价从20美元升至20.5美元</p> <p>• Ascendiant Capital：维持RenovoRx(RNXT
06-06 09:45
Ascendiant Capital Maintains Buy on RenovoRx, Raises Price Target to $11.5
Ascendiant Capital analyst Edward Woo maintains RenovoRx (NASDAQ:RNXT) with a Buy and raises the price target from $11 to $11.5.
06-05 18:33
美股大行评级 | 摩根大通：维持网易"超配"评级，目标价升至135美元；瑞银上调达美航空评级至"买入"
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1131517965561573377.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Armata Pharmaceuticals(ARMP)"买入"评级，目标价从7美元升至9美元</p> <p>• 瑞银：维持爱芬奇(ANF)"买入"评级，目标价从115美
05-20 09:28
HC Wainwright & Co. Reiterates Buy on RenovoRx, Maintains $3 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates RenovoRx (NASDAQ:RNXT) with a Buy and maintains $3 price target.
05-19 18:52
RenovoRx Q1 EPS $(0.08) Beats $(0.09) Estimate, Sales $197.00K Miss $225.00K Estimate
RenovoRx (NASDAQ:RNXT) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.09) by 11.11 percent. This is a 14.29 percent decrease over losses of $(0.07) per share from the same
05-16 04:07
Earnings Scheduled For May 15, 2025
Companies Reporting Before The Bell • Edible Garden (NASDAQ:EDBL) is expected t...
05-15 16:32
RenovoRx Reports Initial Revenue and Clinical Trial Progress
Renovorx, Inc. ( ($RNXT) ) has released its Q4 earnings. Here is a breakdown of...
04-26 12:10
